Conclusions: Combining metformin and L-asparaginase affects DLBCL cell survival by targeting multiple metabolic pathways and may represent a novel therapeutic approach for R/R DLBCL patients. The gene discussed is ASPG; the disease is diffuse large B-cell lymphoma.